An analyst at Morgan Stanley is impressed with the device pipeline at Abbott Laboratories ABT.
The Analyst
Morgan Stanley analyst David Lewis upgraded shares of Abbott Labs from Equal-Weight to Overweight and lifted the price target from $60 to $67.
The Thesis
Abbott Lab's device pipeline, notably Libre and Confirm, could drive an acceleration in organic revenue growth to 6-percent-plus in 2018, Lewis said in a Tuesday note (See the analyst's track record here.)
The pipeline strength coupled with deal synergies could lead to mid-teens earnings per share growth through 2019, Lewis said.
Abbott's risk-reward reverses in 2018, Lewis said, helped by fading of the regulatory issues with St Jude Medical Inc STJ, Alere Inc ALR returning to stable revenue in 2018, China Pediatric Nutrition resuming double-digit growth and the alleviation of balance sheet concerns.
" ... As risks fade, we see an emerging picture of top-tier growth that is not captured in Street expectations for 2018," Lewis said.
"We see multiple expansion on Abbott's premium profile and improving leverage driving outperformance."
The Price Action
Abbott Labs shares are up over 53 percent over the past year.
At the time of writing, the shares were running up 2.85 percent to $58.73.
Related Links:
Abbott Takes Action On FDA Warning Letter
DexCom's Quiet Consolidation After Huge Decline
Photo courtesy of Abbott Laboratories.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.